Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

BACKGROUND: This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL) in real-world context because of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong-Pyo, Hong, Jung Yong, Yoon, Sang Eun, Cho, Junhun, Shim, Joon-Ho, Bang, Yeonghak, Kim, Won Seog, Kim, Seok Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168964/
https://www.ncbi.nlm.nih.gov/pubmed/34093038
http://dx.doi.org/10.2147/CMAR.S309092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168964/
https://www.ncbi.nlm.nih.gov/pubmed/34093038
http://dx.doi.org/10.2147/CMAR.S309092

Ejemplares similares